Uveitis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 129 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Uveitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Uveitis - Pipeline Review, H2 2014', provides an overview of the Uveitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Uveitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Uveitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Uveitis Overview 9
Therapeutics Development 10
Pipeline Products for Uveitis - Overview 10
Pipeline Products for Uveitis - Comparative Analysis 11
Uveitis - Therapeutics under Development by Companies 12
Uveitis - Therapeutics under Investigation by Universities/Institutes 14
Uveitis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Uveitis - Products under Development by Companies 18
Uveitis - Products under Investigation by Universities/Institutes 19
Uveitis - Companies Involved in Therapeutics Development 20
pSivida Corp. 20
Advanced Cell Technology, Inc. 21
Santen Pharmaceutical Co., Ltd. 22
Apitope International NV 23
Novartis AG 24
Pfizer Inc. 25
Enzo Biochem, Inc. 26
Can-Fite BioPharma Ltd. 27
XOMA Corporation 28
HanAll Biopharma Co., Ltd. 29
TxCell SA 30
Endocyte, Inc. 31
to-BBB technologies BV 32
Janssen Biotech, Inc. 33
Icon Bioscience, Inc. 34
Eleven Biotherapeutics 35
AbbVie Inc. 36
OncoNOx ApS 37
Panoptes Pharma Ges.m.b.H. 38
Uveitis - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
sirolimus - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
adalimumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
fluocinolone acetonide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
gevokizumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
secukinumab - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CF-101 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
triamcinolone acetonide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
LFG-316 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
B27-PD - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
triamcinolone acetonide - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
celecoxib - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
HL-036 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
EC-1496 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PA-2612 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
2B3-201 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ATX-UV1 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ATX-UV2 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
OX-1001 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
P-13 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
IBI-70090 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
EC-1669 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
lodamin - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
PP-001 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
INV-17 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
EBI-028 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Col-Treg - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecules to Inhibit Kinase for Uveitis and IBD - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Uveitis - Recent Pipeline Updates 96
Uveitis - Dormant Projects 120
Uveitis - Discontinued Products 121
Uveitis - Product Development Milestones 122
Featured News & Press Releases 122
May 20, 2014: AbbVie Receives Orphan Drug Designation for HUMIRA from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis 122
Apr 04, 2014: Santen Phase III Study Meets Primary Endpoint for the Treatment of Non-Infectious Posterior Segment Uveitis 122
Feb 24, 2014: XOMA Receives Orphan Drug Designation From U.S. FDA for Pyoderma Gangrenosum 123
Jan 07, 2014: TxCell enters Col-Treg into Full Development for the rare disease Autoimmune Uveitis 123
Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN 124
Jul 16, 2013: OphthaliX to Initiate a Phase II study of CF101 for the Treatment of Uveitis 125
Mar 14, 2013: Mitotech completes series of uveitis studies 125
Jan 10, 2013: Clearside Biomedical Announces Plans For Clinical Testing Of CLS1001 Suprachoroidal Injectable Suspension For Treatment Of Some Eye Diseases 125
Dec 27, 2012: Isotechnika Announces Voclosporin Fails To Meet Primary Endpoint In Phase III Uveitis Study 126
Oct 03, 2012: Xoma Initiates Phase III Study Of Gevokizumab In Patients With Non-Infectious Uveitis Currently Controlled By Systemic Treatment 126
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 129
Disclaimer 129

List of Tables
Number of Products under Development for Uveitis, H2 2014 10
Number of Products under Development for Uveitis - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Uveitis - Pipeline by pSivida Corp., H2 2014 20
Uveitis - Pipeline by Advanced Cell Technology, Inc., H2 2014 21
Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 22
Uveitis - Pipeline by Apitope International NV, H2 2014 23
Uveitis - Pipeline by Novartis AG, H2 2014 24
Uveitis - Pipeline by Pfizer Inc., H2 2014 25
Uveitis - Pipeline by Enzo Biochem, Inc., H2 2014 26
Uveitis - Pipeline by Can-Fite BioPharma Ltd., H2 2014 27
Uveitis - Pipeline by XOMA Corporation, H2 2014 28
Uveitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 29
Uveitis - Pipeline by TxCell SA, H2 2014 30
Uveitis - Pipeline by Endocyte, Inc., H2 2014 31
Uveitis - Pipeline by to-BBB technologies BV, H2 2014 32
Uveitis - Pipeline by Janssen Biotech, Inc., H2 2014 33
Uveitis - Pipeline by Icon Bioscience, Inc., H2 2014 34
Uveitis - Pipeline by Eleven Biotherapeutics, H2 2014 35
Uveitis - Pipeline by AbbVie Inc., H2 2014 36
Uveitis - Pipeline by OncoNOx ApS, H2 2014 37
Uveitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2014 38
Assessment by Monotherapy Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 42
Number of Products by Stage and Mechanism of Action, H2 2014 45
Number of Products by Stage and Route of Administration, H2 2014 47
Number of Products by Stage and Molecule Type, H2 2014 49
Uveitis Therapeutics - Recent Pipeline Updates, H2 2014 96
Uveitis - Dormant Projects, H2 2014 120
Uveitis - Discontinued Products, H2 2014 121